Ann: Trading Halt, page-47

the FDA launches a guideline in the face of the corona virus emergency, leaving interpretation and operational decisions to companies engaged in trials. in doing so, the FDA relieves of responsibility and actually discharges them to experimentation.in the specific case involving Neuren, Acadia is responsible for and conducting the trial, which was certainly designed with very high precautions given the particularity and fragility of the patient involved.I therefore believe that Neuren has an extremely prudent attitude and respect for the protocols both towards the families involved in the trial. and towards those who financially support this company. I believe that observing any indication that involves a risk is a due act and a responsibility that will pay off in the future in terms of trust and reliability of this company.I also believe that Acadia has for days already assessed the risk it incurs in the experimentation which is in any case equated to the remaining ongoing trials.here in Italy we are facing the battle against the virus; my wife is in charge of a department of a hospital in the red zone and I can guarantee you that the measures taken now a month ago have absolutely not given access to the virus, so if you want to manage and contain the virus out of a risk environment you can. I believe that Acadia has excellent knowledge of what to do and will not be particularly affected.in a few hours we will know how it will go